Breaking News Instant updates and real-time market news.

XON

Intrexon

$6.73

(0.00%)

, GSK

GlaxoSmithKline

$40.65

(0.00%)

09:40
08/14/19
08/14
09:40
08/14/19
09:40

Unusually active option classes on open August 14th

Unusual total active option classes on open include: Intrexon (XON), GlaxoSmithKline (GSK), Direxion Daily Smal Cap Bull 3X Shares (TNA), SPDR S&P Retail (XRT), Newmont Mining (NEM), US Steel (X), Wal-Mart (WMT), Advanced Micro (AMD), Citi (C), and Bank of America (BAC).

XON

Intrexon

$6.73

(0.00%)

GSK

GlaxoSmithKline

$40.65

(0.00%)

TNA

Terra Nova (Bermuda) Holdings

$55.15

(0.00%)

XRT

S&P Retail Index SPDR

$40.13

(0.00%)

NEM

Newmont Goldcorp

$37.66

(0.00%)

X

U.S. Steel

$12.12

(0.00%)

WMT

Walmart

$107.42

(0.00%)

AMD

AMD

$32.10

(0.00%)

C

Citi

$64.81

(0.00%)

BAC

Bank of America

$27.73

(0.00%)

  • 14

    Aug

  • 15

    Aug

  • 27

    Aug

  • 27

    Aug

  • 06

    Sep

  • 09

    Sep

  • 10

    Sep

  • 15

    Sep

  • 25

    Sep

  • 02

    Oct

  • 15

    Oct

  • 16

    Oct

  • 13

    Nov

XON Intrexon
$6.73

(0.00%)

03/01/19
NORL
03/01/19
DOWNGRADE
Target $10
NORL
Market Perform
Intrexon downgraded to Market Perform from Outperform at Northland
Northland analyst Robert Breza downgraded Intrexon to Market Perform from Outperform after the company reported Q4 results and its auditors issued a going concern opinion. While management indicated that it is pursuing several strategic alternatives, he believes investors will take a wait and see attitude, Breza said. He lowered his price target on Intrexon shares to $10 from $17.
06/18/19
JMPS
06/18/19
NO CHANGE
Target $14
JMPS
Outperform
Surterra cannabinoid pact a positive for Intrexon, says JMP Securities
After Intrexon and privately-held Surterra Wellness announced an exclusive licensing agreement to advance Surterra's cannabinoid production using Intrexon's proprietary yeast fermentation platform, JMP Securities analyst Jason N. Butler said he sees the pact as a positive for Intrexon that supports the value that can be generated across its platforms and sectors. He keeps an Outperform rating and $14 price target on Intrexon shares.
GSK GlaxoSmithKline
$40.65

(0.00%)

07/11/19
WELS
07/11/19
NO CHANGE
WELS
Market right in seeing rebate news as risk to pharmaceuticals, says Wells Fargo
Most pharmaceuticals stocks are down today due to a number of factors, including reports that the Trump Administration is abandoning its plan to lower drug prices by eliminating or restricting pharmacy benefit manager rebating, Wells Fargo analyst David Maris tells investors in a research note. The analyst believes the market is correctly interpreting the move as a potential risk to drugmakers. The absence of a rebating fix "does not mean there will not be a plan to address drug prices, but perhaps a greater risk that the absence of a rebate fix will put additional pressure to come up with ways to actually lower prices in ways that could more greatly impact drug makers than the rebating fix would have," contends Maris. He points out that companies with large cash-pay components of their business, like Allergan (AGN), Establishment Labs (ESTA), Evolus (EOLS), GlaxoSmithKline (GSK), Perrigo (PRGO), Revance (RVNC) and Sientra (SIEN), do not seem to be under as much pressure today as some of their more generic or pharma-concentrated peers. Maris says his Outperform ratings on Allergan, Establishment and Sientra are in part due to their cash-pay concentration
08/13/19
JPMS
08/13/19
INITIATION
JPMS
Neutral
GlaxoSmithKline reinstated with a Neutral at JPMorgan
JPMorgan analyst James Gordon reinstated coverage of GlaxoSmithKline with a Neutral rating and 1,700p price target. The analyst sees the stock near-term being Brexit and currency moves.
07/17/19
RAJA
07/17/19
NO CHANGE
RAJA
Investors shouldn't overreact to drug proposal headlines, says Raymond James
Raymond James analyst Chris Meekins noted that President Donald Trump has indicated an Executive Order on drug pricing is coming soon, but he believes investors "should be cautious not to overreact" to drug related proposal headlines as he "cannot think of a single proposal that was finalized and also survived a court challenge resulting in a negative impact on earnings" yet from the Trump Administration. Given the history of the current White House to date, Meekins said he is increasingly skeptical the Administration will get anything meaningful finalized and overcome legal challenges that will impact drugmakers' earnings before the 2020 election, he tells investors in a healthcare policy note. Publicly traded large cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
07/24/19
MSCO
07/24/19
NO CHANGE
MSCO
Warming could create need for up to $125B more vaccinations, says Morgan Stanley
Morgan Stanley analysts led by Matthew Harrison offered a report sizing the impact on biopharma from climate change. They conclude that warmer temperatures are likely to create more hospitable environments for disease transmission and they cite recent research that suggests 385M-725M more people than today may be exposed to infectious diseases such as dengue, Zika, chickungunya, and yellow fever by 2050. They estimate $50B-$125B of incremental vaccinations may be needed, but see the potential for that figure to be as high as $200B with branded pricing of more complicated vaccines. The companies best positioned to benefit from a rising need for infectious disease vaccines include Sanofi (SNY), GlaxoSmithKline (GSK), Moderna (MRNA), Merck (MRK), Johnson & Johnson's (JNJ) Janssen, Pfizer (PFE) and Takeda (TAK), according to Harrison and the team.
TNA Terra Nova (Bermuda) Holdings
$55.15

(0.00%)

XRT S&P Retail Index SPDR
$40.13

(0.00%)

NEM Newmont Goldcorp
$37.66

(0.00%)

07/03/19
BMOC
07/03/19
DOWNGRADE
Target $45
BMOC
Market Perform
Newmont Goldcorp resumed with a Market Perform from Outperform at BMO Capital
BMO Capital analyst Andrew Kaip downgraded Newmont Goldcorp to Market Perform from Outperform after resuming coverage of the name. He raised his price target for the shares to $45 from $42. While both the acquisition of Goldcorp and the formation of the Nevada joint venture have been accretive events, near-term investor uncertainty regarding the Goldcorp transaction, compounded by recent events at Musselwhite and Penasquito, are likely to "temper investor interest" until Newmont Goldcorp is able to demonstrate value, Kaip tells investors in a research note. As such, the analyst remains cautious until Newmont "demonstrates progress."
07/03/19
BMOC
07/03/19
UPGRADE
Target $20
BMOC
Outperform
Barrick Gold resumed with an Outperform from Market Perform at BMO Capital
BMO Capital analyst Andrew Kaip upgraded Barrick Gold (GOLD) to Outperform from Market Perform and raised his price target for the shares to $20 from $14.50 after resuming coverage of the name. The formation of the Nevada joint venture is a positive for Barrick as the synergies derived from consolidating the Nevada operations with Newmont Goldcorp (NEM) "unlock value," Kaip tells investors in a research note. The analyst this morning also downgraded Newmont Goldcorp to Market Perform from Outperform. He's confident the near-term benefits of the venture outweigh the risks for Barrick.
05/23/19
SBSH
05/23/19
UPGRADE
SBSH
Buy
Newmont Mining upgraded to Buy from Neutral at Citi
05/23/19
SBSH
05/23/19
NO CHANGE
Target $12.5
SBSH
Neutral
Citi upgrades Newmont, downgrades Barrick on resumption of coverage
Citi analyst Alexander Hacking resumed coverage of Barrick Gold and downgraded the shares to Neutral from Buy while lowering his price target to $12.50 from $14. He also resumed coverage of Newmont Mining (NEM) and upgraded the shares to Buy from Neutral while raising his price target for the shares to $40 from $36. The gold sector remains challenged, but Newmont offers better value than Barrick, Hacking tells investors in a research note. After applying Barrick's 1.2 times multiple to Newmont's holdings in the joint venture assets, the analyst sees Newmont's other assets trading at only 0.76 times net asset value. This could be re-rated higher as the market starts to incorporate the joint venture into models, says Hacking.
X U.S. Steel
$12.12

(0.00%)

06/27/19
DBAB
06/27/19
NO CHANGE
DBAB
Hold
Deutsche Bank places 'Catalyst Call' buy on Steel Dynamics
Deutsche Bank analyst Chris Terry placed a "Catalyst Call" buy on shares of Steel Dynamics (STLD) with the stock down 17% since late November 2018. The analyst keeps a Hold rating on the name but sees a shorter term opportunity for upside. Steel Dynamics is ~70% exposed to flat steel, where pricing is now likely bottoming, Terry tells investors in a research note. In addition, U.S. Steel (X) recently announced 2.5mt of capacity curtailments which could improve sentiment towards pricing and the future supply/demand balance, adds the analyst.
06/26/19
JEFF
06/26/19
NO CHANGE
JEFF
Nucor flat rolled price increase likely to help sentiment, says Jefferies
After Nucor (NUE) announced a $40/t flat rolled price increase yesterday, which was the first increase since February, Jefferies analyst Martin Englert said he thinks peers are likely to follow. While the increase may not immediately raise prices, it is a move in the right direction that aids more positive sector sentiment, Englert tell investors. The analyst, who advises investors to increase exposure to steel stocks, names Nucor, Steel Dynamics (STLD), Cleveland-Cliffs (CLF) and Commercial Metals (CMC) as his top U.S. picks Other publicly traded companies in the steel space include AK Steel (AKS), ArcelorMittal (MT), TimkenSteel (TMST) and U.S. Steel (X).
06/19/19
06/19/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Lamb Weston (LW) upgraded to Buy from Neutral at Goldman Sachs with analyst Adam Samuelson saying the shares offer an "attractive valuation risk/reward," after declining 18.6% year-to-date. 2. TripAdvisor (TRIP) upgraded to Buy from Hold at SunTrust with analyst Naved Khan noting that the market valuation is placing more emphasis on the company's EBITDA multiple of the slower-growing Core business, even though its Experiences segment has generated annual growth of over 30% and now represents nearly a third of total sales. 3. Six Flags (SIX) upgraded to Outperform from Neutral at Wedbush with analyst James Hardiman stating believes that a number of potential catalysts line up nicely for the company, most notably Per-Capita spending improvements driven by the Membership 2.0 program, positive news flow from the company's international business and easy weather comparisons. 4. National CineMedia (NCMI) upgraded to Outperform from Neutral at Wedbush with analyst Michael Pachter saying he is less concerned about reserved seating driving later arrivals as the company has shown that it can recoup ad dollars elsewhere. 5. U.S. Steel (X) upgraded to Buy from Sell at Vertical Group with analyst Gordon Johnson after the company did the "unthinkable" and idled two U.S. plants and one in the EU. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/19/19
VERF
06/19/19
UPGRADE
VERF
Buy
U.S. Steel upgraded to Buy from Sell at Vertical Group
Vertical Group analyst Gordon Johnson double upgraded U.S. Steel to Buy from Sell after the company did the "unthinkable" and idled two U.S. plants and one in the EU. He sees the stock likely moving higher after the actions, he tells investors.
WMT Walmart
$107.42

(0.00%)

07/17/19
FBCO
07/17/19
NO CHANGE
Target $195
FBCO
Outperform
Walmart partnership could serve as driver for Advance Auto Parts, says Credit Suisse
Credit Suisse analyst Seth Sigman notes that Advance Auto (AAP) has launched what appears to be the initial phases of its partnership with Walmart (WMT), adding about 5,000 SKUs to the Walmart website. The analyst ultimately believes that, if done right, this could serve as an incremental driver for Advance Auto Parts, benefiting from Walmart's growing online traffic and product offering. That said, more important for the stock in short term will be improving comps after the slow start and weather impact in Q2, along with instilling confidence in the margin outlook, he contends. Sigman has an Outperform rating and $195 price target on Advance Auto Parts' shares.
07/23/19
LOOP
07/23/19
NO CHANGE
Target $115
LOOP
Hold
Walmart price target raised to $115 from $106 at Loop Capital
Loop Capital analyst Andrew Wolf raised his price target on Walmart to $115, saying the company's recently announced consolidation of the U.S. stores and e-commerce divisions' supply chains and financial management is positive for its continued expansion in omnichannel merchandising. The analyst notes that the perception of this consolidation as a sign of "retrenchment and/or infighting at the senior operating ranks" is mistaken. Wolf is keeping his Hold rating on Walmart however, citing its current valuation.
08/12/19
BARD
08/12/19
NO CHANGE
Target $115
BARD
Outperform
Baird comfortable with Walmart expectations ahead of Q2 results
Baird analyst Peter Benedict said he remains comfortable with Q2 Walmart expectations ahead of its report on Thursday. The analyst believes comp trends will remain solid and although he expects pressure on margins from Flipkart, he sees the company continuing to manage and drive SG&A efficiencies. Benedict reiterated his Outperform rating and $115 price target on Walmart shares.
07/15/19
CHLM
07/15/19
NO CHANGE
CHLM
Sell
PetMed CEO amendment hints at exploration of alternatives, says Craig-Hallum
Craig-Hallum analyst Kevin Ellich noted that PetMed Express (PETS) filed an 8K after the close on Friday to disclose that it amended CEO Mendo Akdag's employment agreement to add the language "for Good Reason" to the "Change in Control" section. He reads this change as a hint that an exploration of strategic alternatives could be upcoming, though he doesn't think there is anything imminent in the works. The analyst, who suspects there is further downside to Street estimates for PetMed given increased competition from Chewy (CHWY), Walmart (WMT), Petco and other online retailers, keeps a Sell rating on PetMed shares.
AMD AMD
$32.10

(0.00%)

08/12/19
COWN
08/12/19
NO CHANGE
Target $42
COWN
Outperform
AMD price target raised to $42, remains a top pick at Cowen
Cowen analyst Matthew Ramsay raised his price target on AMD to $42 from $40 and said it remains a top pick following recent investor meetings. The analyst said with solid execution, the path to material share gains is clear as the meeting highlighted company leadership, performance, power and pricing. Ramsay said AMD remains a top pick and he reiterated his Outperform rating on AMD shares.
08/12/19
LOOP
08/12/19
INITIATION
Target $32
LOOP
Hold
AMD initiated with a Hold at Loop Capital
Loop Capital analyst Cody Acree started AMD with a Hold rating and $32 price target.
08/13/19
08/13/19
INITIATION
Target $32

Hold
AMD initiated with a Hold at Loop Capital
As previously reported, Loop Capital analyst Cody Acree initiated AMD (AMD) with a Hold rating and a price target of $32. The analyst is positive on the company's "significant transformation" since 2016 that yielded an attractive growth rate and operational profitability, noting that while many of its latest next-generation platforms are just starting to come to market, early reviews indicate "impressive performance" against comparable offerings from Intel (INTC) and Nvidia (NVDA). Acree believes that AMD is "well positioned" to gain material market share across its primary target markets, but also sees the stock as "fairly valued".
08/13/19
08/13/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Simply Good Foods (SMPl) initiated with an Outperform at Bernstein. 2. AMD (AMD) and Intel (INTC) initiated with a Hold at Loop Capital. 3. Cronos Group (CRON) initiated with an Overweight at Piper Jaffray. 4. Medallia (MDLA) initiated with an Outperform at William Blair, Wells Fargo, and Oppenheimer, a Buy at Roth Capital, Needham, and BofA/Merrill, as well as a Neutral at Credit Suisse and Citi. 5. Sempra Energy (SRE) initiated with an Equal Weight at Barclays. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
C Citi
$64.81

(0.00%)

07/26/19
KBWI
07/26/19
UPGRADE
Target $86
KBWI
Outperform
Citi upgraded to Outperform from Market Perform at Keefe Bruyette
Keefe Bruyette analyst Brian Kleinhanzl upgraded Citi to Outperform from Market Perform and raised his price target for the shares to $86 from $74. The analyst raised the Universal Bank group to Overweight from Market Weight as he believes that the economic cycle will be extended following Federal Reserve rate cuts. Further, the current valuations for the group are attractive "as we are not as late cycle as feared," Kleinhanzl tells investors in a research note. He also expects rotation back to financial stocks after investors have reduced allocations to the group. Investors should position for better macro conditions with a focus on owning money center banks and select brokers, says Kleinhanzl.
07/26/19
07/26/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Goldman Sachs (GS) and Citi (C) upgraded to Outperform from Market Perform at Keefe Bruyette. 2. Ambev (ABEV) upgraded to Neutral from Underweight at JPMorgan with analyst Lucas Ferreira saying the post-earnings share rally shows that investors are chasing good growth stories to play Brazil's economic recovery. 3. West Pharmaceutical (WST) upgraded to Neutral from Underperform at BofA/Merrill with analyst Derik de Bruin saying that over the course of the first half, the company addressed his prior concerns around organic revenue growth and product mix trends while also boosting its operating margins and generating higher free cash flows. 4. Union Pacific (UNP) upgraded to Overweight from Neutral at Atlantic Equities, while CSX (CSX) was upgraded to Neutral from Underweight. 5. Hasbro (HAS) upgraded to Buy from Hold at Argus with analyst John Staszak citing the company's dominant position with a range of "strong" brands as well as in the big-screen business. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/23/19
WELS
07/23/19
DOWNGRADE
Target $50
WELS
Market Perform
Wells Fargo downgrades Zions Bancorp, continues to prefer larger peers
Wells Fargo analyst Mike Mayo downgraded Zions Bancorp (ZION) to Market Perform from Outperform and lowered his price target for the shares to $50 from $62. The company's weaker than expected Q2 results help illustrate why larger and more diversified banks are preferable investments in the current environment, Mayo tells investors in a research note. Zions faces above average exposure to interest rate driven revenues without offsets commensurate with some of its larger peers, contends the analyst. He believes estimates for Zions need to come down and that the bank's and efficiency gains are likely to be offset by rate pressures. Mayo's top pick is Citi (C).
07/26/19
KBWI
07/26/19
UPGRADE
Target $260
KBWI
Outperform
Goldman Sachs upgraded to Outperform from Market Perform at Keefe Bruyette
Keefe Bruyette analyst Brian Kleinhanzl upgraded Goldman Sachs (GS) to Outperform from Market Perform and raised his price target for the shares to $260 from $225. The analyst, who also upgraded Citi (C) and Bank of America (BAC) today to Outperform, raised the Universal Bank group to Overweight from Market Weight as he believes the economic cycle will be extended following rate cuts from the Federal Reserve. Further, the current valuations for the group are attractive "as we are not as late cycle as feared," Kleinhanzl tells investors in a research note. He also expects rotation back to financial stocks after investors have reduced allocations to the group. Investors should position for better macro conditions with a focus on owning money center banks and select brokers, says Kleinhanzl.
BAC Bank of America
$27.73

(0.00%)

07/26/19
KBWI
07/26/19
UPGRADE
Target $36
KBWI
Outperform
Bank of America upgraded to Outperform from Market Perform at Keefe Bruyette
Keefe Bruyette analyst Brian Kleinhanzl upgraded Bank of America to Outperform from Market Perform and raised his price target for the shares to $36 from $32. The analyst raised the Universal Bank group to Overweight from Market Weight as he believes that the economic cycle will be extended following Federal Reserve rate cuts. Further, the current valuations for the group are attractive "as we are not as late cycle as feared," Kleinhanzl tells investors in a research note. He also expects rotation back to financial stocks after investors have reduced allocations to the group. Investors should position for better macro conditions with a focus on owning money center banks and select brokers, says Kleinhanzl.
06/18/19
06/18/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Bank of America (BAC) upgraded to Outperform from Market Perform at BMO Capital with analyst James Fotheringham expecting upward consensus estimates revisions and a "multiple re-rating" to drive 34% total return in the shares. 2. SunPower (SPWR), SunRun (RUN) upgraded to Buy from Neutral as SolarEdge (SEDG) upgraded to Neutral from Sell at Goldman Sachs with analyst Brian Lee anticipating "volume tailwinds" in the second half of 2019 given the recent signs of strength in the sector's financing environment. 3. CNH Industrial (CNHI) upgraded to Hold from Sell at Deutsche Bank with analyst Chad Dillard saying he's turning positive on North America large agriculture. 4. U.S. Cellular (USM), Telephone and Data (TDS) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Simon Flannery stating that he sees both stocks as "very attractively valued" with each down over 20% from their recent peak levels. 5. Prosperity Bancshares (PB) upgraded to Market Perform from Underperform at Raymond James with analyst Michael Rose saying the LegacyTexas Financial (LTXB) transaction provides meaningful scale in some of the most attractive markets in the country. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/28/19
WELS
06/28/19
NO CHANGE
WELS
Market Perform
Impacts of Bank of America decision manageable for First Data, says Wells Fargo
Wells Fargo analyst Timothy Willi sees three potential outcomes as Bank of America (BAC) reportedly weighs the exit of its joint venture with First Data (FDC). The joint venture can be dissolved, the terms can be renegotiated more favorably for Bank of America, and/or Bank of America can acquire an increased ownership of the venture, Willi tells investors in a research note. The current agreement ends in June 2020 and any party wishing to terminate must give one year notice, the analyst adds. While he believes that each of these scenarios could be an incremental negative for First Data, the analyst thinks the impacts are either "manageable or immaterial" in the context of a combined Fiserv (FISV), First Data. Willi has a Market Perform rating on First Data.

TODAY'S FREE FLY STORIES

YCBD

cbdMD

$5.03

0.31 (6.57%)

12:19
09/20/19
09/20
12:19
09/20/19
12:19
Hot Stocks
Breaking Hot Stocks news story on cbdMD »

cbdMD trading halted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
09/20/19
09/20
12:17
09/20/19
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
09/20/19
09/20
12:16
09/20/19
12:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SONO

Sonos

$15.01

-0.065 (-0.43%)

12:15
09/20/19
09/20
12:15
09/20/19
12:15
Options
Sonos put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRAM

Everspin Technologies

$6.52

-0.09 (-1.36%)

12:12
09/20/19
09/20
12:12
09/20/19
12:12
Conference/Events
Everspin Technologies management to meet with Needham »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Sep

  • 12

    Nov

SAIC

SAIC

$84.64

0.76 (0.91%)

12:11
09/20/19
09/20
12:11
09/20/19
12:11
Recommendations
SAIC analyst commentary  »

SAIC recompete bid on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALNY

Alnylam

$86.18

1.5 (1.77%)

12:11
09/20/19
09/20
12:11
09/20/19
12:11
Conference/Events
Alnylam management to meet with Needham »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

  • 02

    Oct

  • 04

    Feb

SNPS

Synopsys

$137.26

0.09 (0.07%)

12:10
09/20/19
09/20
12:10
09/20/19
12:10
Conference/Events
Synopsys management to meet with Needham »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Sep

TYL

Tyler Technologies

$259.35

-0.22 (-0.08%)

12:10
09/20/19
09/20
12:10
09/20/19
12:10
Conference/Events
Tyler Technologies management to meet with JMP Securities »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

AAPL

Apple

$220.96

0.05 (0.02%)

, MCD

McDonald's

$210.55

-0.01 (-0.00%)

12:02
09/20/19
09/20
12:02
09/20/19
12:02
On The Fly
Fly Intel: Wall Street's top stories at midday »

Stocks are mixed at…

AAPL

Apple

$220.96

0.05 (0.02%)

MCD

McDonald's

$210.55

-0.01 (-0.00%)

FB

Facebook

$190.17

0.02 (0.01%)

MDR

McDermott

$2.70

1.12 (70.89%)

CRC

California Resources

$11.86

1.96 (19.80%)

ROKU

Roku

$114.30

-19.41 (-14.52%)

W

Wayfair

$123.39

-5.275 (-4.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 23

    Sep

  • 24

    Sep

  • 27

    Oct

SCS

Steelcase

$18.34

1.57 (9.36%)

12:00
09/20/19
09/20
12:00
09/20/19
12:00
Hot Stocks
Steelcase rises 9.6% »

Steelcase is up 9.6%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 15

    Oct

  • 16

    Oct

IBN

ICICI Bank

$11.88

1.11 (10.31%)

12:00
09/20/19
09/20
12:00
09/20/19
12:00
Hot Stocks
ICICI Bank rises 10.2% »

ICICI Bank is up 10.2%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRC

California Resources

$11.75

1.85 (18.69%)

12:00
09/20/19
09/20
12:00
09/20/19
12:00
Hot Stocks
California Resources rises 18.8% »

California Resources is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNY

Sanofi

$45.72

0.83 (1.85%)

11:54
09/20/19
09/20
11:54
09/20/19
11:54
Upgrade
Sanofi rating change  »

Morgan Stanley upgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 27

    Sep

  • 02

    Oct

TSLA

Tesla

$242.92

-3.59 (-1.46%)

11:50
09/20/19
09/20
11:50
09/20/19
11:50
Options
Bearish Dec put spread collar in Tesla opened for a small debit »

Bearish Dec put spread…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

SNY

Sanofi

$45.61

0.72 (1.60%)

11:46
09/20/19
09/20
11:46
09/20/19
11:46
Upgrade
Sanofi rating change  »

Sanofi upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 27

    Sep

  • 02

    Oct

CRZBY

Commerzbank

$0.00

(0.00%)

11:46
09/20/19
09/20
11:46
09/20/19
11:46
Hot Stocks
Commerzbank develops draft of new strategy, to cut 4,300 jobs »

Commerzbank announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHHBY

Roche

$0.00

(0.00%)

11:45
09/20/19
09/20
11:45
09/20/19
11:45
Hot Stocks
Roche reports FDA approves cobas Babesia test »

Roche announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Nov

PBR

Petrobras

$14.44

-0.09 (-0.62%)

11:42
09/20/19
09/20
11:42
09/20/19
11:42
Periodicals
Petrobras suffers increase in fuel theft from pipelines, Reuters reports »

Petrobras is confronting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ROKU

Roku

$116.20

-17.51 (-13.10%)

11:40
09/20/19
09/20
11:40
09/20/19
11:40
Options
Roku leads single stock option volume with over 250K contracts in 90 minutes »

Roku leads single stock…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:40
09/20/19
09/20
11:40
09/20/19
11:40
General news
More from Rosengren: he reiterated his dissent »

More from Rosengren: he…

RYAAY

Ryanair

$62.91

0.43 (0.69%)

11:38
09/20/19
09/20
11:38
09/20/19
11:38
Hot Stocks
Ryanair U.K. pilots union cancels five further strike days »

The British Airline…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDR

McDermott

$2.74

1.16 (73.42%)

11:35
09/20/19
09/20
11:35
09/20/19
11:35
Recommendations
McDermott analyst commentary  »

McDermott's plans to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

VAL

Valaris

$6.76

-0.01 (-0.15%)

11:35
09/20/19
09/20
11:35
09/20/19
11:35
Options
Valaris Plc put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:35
09/20/19
09/20
11:35
09/20/19
11:35
General news
NY Fed announced it will conduct daily repo operations »

NY Fed announced it will…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.